We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Amgen Sues Genentech To Shield Avastin Biosimilar

Law360, San Francisco (October 6, 2017, 10:13 PM EDT) -- Amgen Inc. filed a suit in California federal court Friday seeking a declaration that 27 patents related to Genentech’s cancer treatment Avastin are invalid, unenforceable and aren’t infringed by Amgen’s biologic, which won U.S. Food and Drug Administration approval last month.

The suit follows months of stalled negotiations over bevacizumab, an antibody product used in the drug. The biologic — a genetically engineered protein that can be medically introduced to the immune system — caused a standoff between Genentech, which is trying to protect property rights...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Amgen Inc v. Genentech, Inc. et al


Case Number

2:17-cv-07349

Court

California Central

Nature of Suit

Patent

Judge

George H. Wu

Date Filed

October 6, 2017

Law Firms

Companies

Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.